1
|
Badr S, Rezq S, Abdelghany RH. Endogenous β-endorphin plays a pivotal role in angiotensin II-mediated central neurochemical changes and pressor response. Chem Biol Interact 2021; 342:109475. [PMID: 33872574 DOI: 10.1016/j.cbi.2021.109475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2021] [Revised: 03/08/2021] [Accepted: 04/12/2021] [Indexed: 10/21/2022]
Abstract
Endorphins are endogenous opioid neuropeptides that are mainly produced from pituitary gland in response to pain and different triggers including interleukin 1 beta (IL-1β) and corticotropin-releasing factor (CRF). Angiotensin II (Ang II) can stimulate β-endorphin production, but the exact molecular mechanisms involved in this effect, and the role of the released β-endorphin in Ang II-mediated pressor response remain elusive. Male rats were injected with IL-1β receptor antagonist (IL-1Ra, 100 μg/kg), the CRF receptor blocker, astressin (20 μg/rat) or a combination of both, prior to Ang II injection (200 μg/kg). Another group of rats was given naloxone (1.6 mg/kg) or telmisartan (5 mg/kg) before Ang II injection. Blood pressure and serum and Paraventricular nucleus (PVN) β-endorphin were detected. Moreover, IL-1β and CRF as well as markers of oxidative stress [malondialdehyde (MDA) and superoxide dismutase (SOD)], inflammation [C-reactive protein (CRP)] and neuronal activation (c-Fos, l-glutamate, and phosphorylated ERK) were measured in the PVN of different groups. Ang II induced a pressor response and increased serum and PVN β-endorphin levels that were attenuated in rats pre-treated with astressin or/and IL-1Ra. Moreover, Ang II increased PVN oxidative stress, inflammation and neuronal activation. Telmisartan abolished the previous effects, while naloxone, astressin and IL-1Ra aggravated Ang II-mediated pressor response and most of the biochemical changes. These findings suggest that, Ang II can induce β-endorphin release via increasing both IL-1β and CRF levels which in result mitigates Ang II-mediated central responses. This study highlights β-endorphin as a possible target for treating hypertension.
Collapse
Affiliation(s)
- Safy Badr
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Samar Rezq
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
| | - Rasha H Abdelghany
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| |
Collapse
|
2
|
Nuclear Receptors as Regulators of Pituitary Corticotroph Pro-Opiomelanocortin Transcription. Cells 2020; 9:cells9040900. [PMID: 32272677 PMCID: PMC7226830 DOI: 10.3390/cells9040900] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2020] [Revised: 03/29/2020] [Accepted: 04/01/2020] [Indexed: 12/16/2022] Open
Abstract
The hypothalamic–pituitary–adrenal (HPA) axis plays a critical role in adaptive stress responses and maintaining organism homeostasis. The pituitary corticotroph is the central player in the HPA axis and is regulated by a plethora of hormonal and stress related factors that synergistically interact to activate and temper pro-opiomelanocortin (POMC) transcription, to either increase or decrease adrenocorticotropic hormone (ACTH) production and secretion as needed. Nuclear receptors are a family of highly conserved transcription factors that can also be induced by various physiologic signals, and they mediate their responses via multiple targets to regulate metabolism and homeostasis. In this review, we summarize the modulatory roles of nuclear receptors on pituitary corticotroph cell POMC transcription, describe the unique and complex role these factors play in hypothalamic–pituitary–adrenal axis (HPA) regulation and discuss potential therapeutic targets in disease states.
Collapse
|
3
|
Cawley NX, Li Z, Loh YP. 60 YEARS OF POMC: Biosynthesis, trafficking, and secretion of pro-opiomelanocortin-derived peptides. J Mol Endocrinol 2016; 56:T77-97. [PMID: 26880796 PMCID: PMC4899099 DOI: 10.1530/jme-15-0323] [Citation(s) in RCA: 109] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2016] [Accepted: 02/15/2016] [Indexed: 12/15/2022]
Abstract
Pro-opiomelanocortin (POMC) is a prohormone that encodes multiple smaller peptide hormones within its structure. These peptide hormones can be generated by cleavage of POMC at basic residue cleavage sites by prohormone-converting enzymes in the regulated secretory pathway (RSP) of POMC-synthesizing endocrine cells and neurons. The peptides are stored inside the cells in dense-core secretory granules until released in a stimulus-dependent manner. The complexity of the regulation of the biosynthesis, trafficking, and secretion of POMC and its peptides reflects an impressive level of control over many factors involved in the ultimate role of POMC-expressing cells, that is, to produce a range of different biologically active peptide hormones ready for action when signaled by the body. From the discovery of POMC as the precursor to adrenocorticotropic hormone (ACTH) and β-lipotropin in the late 1970s to our current knowledge, the understanding of POMC physiology remains a monumental body of work that has provided insight into many aspects of molecular endocrinology. In this article, we describe the intracellular trafficking of POMC in endocrine cells, its sorting into dense-core secretory granules and transport of these granules to the RSP. Additionally, we review the enzymes involved in the maturation of POMC to its various peptides and the mechanisms involved in the differential processing of POMC in different cell types. Finally, we highlight studies pertaining to the regulation of ACTH secretion in the anterior and intermediate pituitary and POMC neurons of the hypothalamus.
Collapse
Affiliation(s)
- Niamh X Cawley
- Section on Cellular NeurobiologyEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA
| | - Zhaojin Li
- Section on Cellular NeurobiologyEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA
| | - Y Peng Loh
- Section on Cellular NeurobiologyEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA
| |
Collapse
|
4
|
Minami M, Katayama T, Satoh M. Brain Cytokines and Chemokines: Roles in Ischemic Injury and Pain. J Pharmacol Sci 2006; 100:461-70. [PMID: 16682788 DOI: 10.1254/jphs.crj06005x] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Abstract
Cytokines and chemokines were originally identified as essential mediators for inflammatory and immune responses. Enhanced production and release of cytokines/chemokines are observed also in the central nervous system (CNS) under diverse pathological conditions. There is growing evidence showing that brain cytokines/chemokines play crucial roles in the neuro-glio-vascular interaction underlying the pathology of various brain disorders and therefore are potential targets for development of novel and effective therapeutics for CNS diseases. Here the evidence of the involvement of cytokines/chemokines in ischemic brain injury and pain is reviewed.
Collapse
Affiliation(s)
- Masabumi Minami
- Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapparo, Japan.
| | | | | |
Collapse
|
5
|
Abstract
One of the truly remarkable discoveries in modern biology is the finding that the nervous system and immune system use a common chemical language for intra- and inter-system communication. This review will discuss some of the pivotal results that deciphered this chemical language. Specifically the nervous and immune systems produce a common set of peptide and nonpeptide neurotransmitters and cytokines that act on a common repertoire of receptors in the two systems. The paper will also review more recent studies that have delineated hardwired and humoral pathways for such bidirectional communication. This is discussed in the context of the idea that the sharing of ligands and receptors allows the immune system to serve as the sixth sense that notifies the nervous system of the presence of entities, such as viruses and bacteria, that are imperceptible to the classic senses. Lastly, this review will suggest ways to apply the newfound knowledge of the sixth sense to understand a placebo effect and to treat human disease.
Collapse
Affiliation(s)
- J E Blalock
- Department of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham, AL, USA.
| |
Collapse
|
6
|
Ooi GT, Tawadros N, Escalona RM. Pituitary cell lines and their endocrine applications. Mol Cell Endocrinol 2004; 228:1-21. [PMID: 15541569 DOI: 10.1016/j.mce.2004.07.018] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/17/2004] [Accepted: 07/15/2004] [Indexed: 10/26/2022]
Abstract
The pituitary gland is an important component of the endocrine system, and together with the hypothalamus, exerts considerable influence over the functions of other endocrine glands. The hypothalamus either positively or negatively regulates hormonal productions in the pituitary through its release of various trophic hormones which act on specific cell types in the pituitary to secrete a variety of pituitary hormones that are important for growth and development, metabolism, reproductive and nervous system functions. The pituitary is divided into three sections-the anterior lobe which constitute the majority of the pituitary mass and is composed primarily of five hormone-producing cell types (thyrotropes, lactotropes, corticotropes, somatotropes and gonadotropes) each secreting thyrotropin, prolactin, ACTH, growth hormone and gonadotropins (FSH and LH) respectively. There is also a sixth cell type in the anterior lobe-the non-endocrine, agranular, folliculostellate cells. The intermediate lobe produces melanocyte-stimulating hormone and endorphins, whereas the posterior lobe secretes anti-diuretic hormone (vasopressin) and oxytocin. Representative cell lines of all the six cell types of the anterior pituitary have been established and have provided valuable information on genealogy of the various cell lineages, endocrine feedback control of hormone synthesis and secretions, intrapituitary interactions between the various cell types, as well as the role of specific transcription factors that determine each differentiated cell phenotype. In this review, we will discuss the morphology and function of the cell types that make up the anterior pituitary, and the characteristics of the various functional anterior pituitary cell systems that have been established to be representative of each anterior pituitary cell lineage.
Collapse
Affiliation(s)
- Guck T Ooi
- Prince Henry's Institute of Medical Research, Monash Medical Centre, Block E, Level 4, 246 Clayton Road, Clayton, Victoria 3168, Australia.
| | | | | |
Collapse
|
7
|
Kovalovsky D, Paez Pereda M, Labeur M, Renner U, Holsboer F, Stalla GK, Arzt E. Nur77 induction and activation are necessary for interleukin-1 stimulation of proopiomelanocortin in AtT-20 corticotrophs. FEBS Lett 2004; 563:229-33. [PMID: 15063754 DOI: 10.1016/s0014-5793(04)00303-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2004] [Revised: 03/03/2004] [Accepted: 03/08/2004] [Indexed: 11/23/2022]
Abstract
Nur77 and Nurr1 are critical for proopiomelanocortin (POMC) regulation by corticotrophin releasing hormone (CRH) in corticotrophs. We analyze the regulation and activity of Nur77 by interleukin (IL)-1 in AtT-20 corticotrophic cells and its consequences on POMC regulation. IL-1 induces Nur77 and not Nurr1 mRNA and shows an increased transcriptional activity on the NurRE site, an effect dependent of p38 protein kinase activity. A NurRE mutation abrogates POMC promoter transcription by IL-1 and a stable AtT-20 clone overexpressing a dominant negative form of Nur77 is unresponsive to IL-1-dependent POMC induction and adrenocorticotrophin (ACTH) secretion. These results demonstrate that Nur77 is essential for POMC stimulation by IL-1 in corticotrophs.
Collapse
Affiliation(s)
- Damian Kovalovsky
- Departamento de Fisiología y Biología Molecular, FCEN, Universidad de Buenos Aires and CONICET, Buenos Aires, Argentina
| | | | | | | | | | | | | |
Collapse
|
8
|
Barkhudaryan N, Dunn AJ. Molecular mechanisms of actions of interleukin-6 on the brain, with special reference to serotonin and the hypothalamo-pituitary-adrenocortical axis. Neurochem Res 1999; 24:1169-80. [PMID: 10485589 DOI: 10.1023/a:1020720722209] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Biological activities of the multifunctional cytokine, interleukin-6 (IL-6) include stimulation of B cell proliferation, immunoglobulin production, and initiation of the acute-phase response. IL-6 affects the CNS in that it activates the hypothalamo-pituitary-adrenocortical (HPA) axis and increases brain tryptophan and serotonin metabolism. IL-6 has been proposed as an important mediator of interaction between the neuroendocrine and immune systems. The peripheral and central effects of IL-6 are presumably mediated through its membrane receptor (IL-6R). IL-6, IL-6R and their respective mRNAs have been detected in several brain regions. Although the functions of cytokines overlap considerably, each displays its own characteristic properties. Expression of IL-6 in the brain has been observed in several CNS disorders, some of which have been associated with disorders of serotonin metabolism. It is proposed that interactions between IL-6 and brain serotonin is a complex process which involves corticotropin-releasing factor (CRF) and opioid peptides. It is likely that the molecular mechanisms underlying the actions of IL-6 on the HPA axis and its other brain functions involve the integrated effects of glutamate, Ca2+, 3',5'-cyclic AMP, protein kinase C, and other metabolic pathways.
Collapse
Affiliation(s)
- N Barkhudaryan
- Department of Pharmacology and Therapeutics, Louisiana State University Medical Center, Shreveport 71130-3932, USA
| | | |
Collapse
|
9
|
Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999; 79:1-71. [PMID: 9922367 DOI: 10.1152/physrev.1999.79.1.1] [Citation(s) in RCA: 808] [Impact Index Per Article: 32.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Glucocorticoids are hormone products of the adrenal gland, which have long been recognized to have a profound impact on immunologic processes. The communication between immune and neuroendocrine systems is, however, bidirectional. The endocrine and immune systems share a common "chemical language," with both systems possessing ligands and receptors of "classical" hormones and immunoregulatory mediators. Studies in the early to mid 1980s demonstrated that monocyte-derived or recombinant interleukin-1 (IL-1) causes secretion of hormones of the hypothalamic-pituitary-adrenal (HPA) axis, establishing that immunoregulators, known as cytokines, play a pivotal role in this bidirectional communication between the immune and neuroendocrine systems. The subsequent 10-15 years have witnessed demonstrations that numerous members of several cytokine families increase the secretory activity of the HPA axis. Because this neuroendocrine action of cytokines is mediated primarily at the level of the central nervous system, studies investigating the mechanisms of HPA activation produced by cytokines take on a more broad significance, with findings relevant to the more fundamental question of how cytokines signal the brain. This article reviews published findings that have documented which cytokines have been shown to influence hormone secretion from the HPA axis, determined under what physiological/pathophysiological circumstances endogenous cytokines regulate HPA axis activity, established the possible sites of cytokine action on HPA axis hormone secretion, and identified the potential neuroanatomic and pharmacological mechanisms by which cytokines signal the neuroendocrine hypothalamus.
Collapse
Affiliation(s)
- A V Turnbull
- The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California, USA
| | | |
Collapse
|
10
|
Arzt E, Pereda MP, Castro CP, Pagotto U, Renner U, Stalla GK. Pathophysiological role of the cytokine network in the anterior pituitary gland. Front Neuroendocrinol 1999; 20:71-95. [PMID: 9882537 DOI: 10.1006/frne.1998.0176] [Citation(s) in RCA: 89] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Recent evidence has demonstrated that cytokines and other growth factors act in the anterior pituitary gland. Using the traditional criteria employed to determine autocrine or paracrine functions our review shows that, in addition to their role as lymphocyte messengers, certain cytokines are autocrine or paracrine regulators of anterior pituitary function and growth. The cytokines known to regulate and/or be expressed in the anterior pituitary include the inflammatory cytokine family (IL-1 and its endogenous antagonist, IL-1ra; TNF-alpha, and IL-6), the Th1-cytokines (IL-2 and IFN-gamma), and other cytokines such as LIF, MIF, and TGF-beta. This review examines at the cellular, molecular, and physiological levels whether: (1) each cytokine alters some aspect of pituitary physiology; (2) receptors for the cytokine are expressed in the gland; and (3) the cytokine is produced in the anterior pituitary. Should physiological stimuli regulate pituitary cytokine production, this would constitute additional proof of their autocrine/paracrine role. In this context, we analyze in this review the current literature on the actions of cytokines known to regulate anterior pituitary hormone secretion, selecting the in vivo studies that support the direct action of the cytokine in the anterior pituitary. Further support for direct regulatory action is provided by in vitro studies, in explant cultures or pituitary cell lines. The cytokine receptors that have been demonstrated in the pituitary of several species are also discussed. The endogenous production of the homologous cytokines and the regulation of this expression are analyzed. The evidence indicating that cytokines also regulate the growth and proliferation of pituitary cells is reviewed. This action is particularly important since it suggests that intrinsically produced cytokines may play a role in the pathogenesis of pituitary adenomas. The complex cell to cell communication involved in the action of these factors is discussed.
Collapse
Affiliation(s)
- E Arzt
- Dept. de Biología, FCEN, Buenos Aires, Universidad de Buenos Aires, Argentina
| | | | | | | | | | | |
Collapse
|
11
|
Ruzicka BB, Akil H. The interleukin-1beta-mediated regulation of proenkephalin and opioid receptor messenger RNA in primary astrocyte-enriched cultures. Neuroscience 1997; 79:517-24. [PMID: 9200734 DOI: 10.1016/s0306-4522(96)00669-0] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Opioids have been found to modulate the function of the immune system by regulating the biochemical and proliferative properties of its cellular components. The interaction of opioid and immune systems, however, is not unidirectional, but rather, bidirectional in nature. In the CNS, one cellular target of immune system activation is the astrocytes, glial cells known to synthesize proenkephalin. We have recently shown that these cells also express the messenger RNA transcripts for the opioid receptors mu, delta and kappa, raising the question of the functional significance of this opioid peptide and the related receptors in the astrocytes. That is, why do astrocytes express proenkephalin and opioid receptors, and are these molecules responsive to a factor to which the astrocytes could be exposed in vivo? Furthermore, do these molecules respond to this factor in a region-specific fashion? In the present study, in order to characterize the astrocytic opioid response to an immune factor, we examined the concomitant regulation of mu, delta, kappa and proenkephalin messenger RNAs by interleukin-1beta (1 ng/ml=60 pM, 24 h) in primary astrocyte-enriched cultures derived from the rat (post-natal day 1-2) cortex, striatum, cerebellum, hippocampus and hypothalamus. Interleukin-1beta treatment was found to increase by 55-75% the level of mu receptor messenger RNA in striatal, cerebellar and hippocampal cultures, but not in cultures derived from the cortex or hypothalamus. However, the cytokine had no effect on the level of delta receptor messenger RNA in any of the five cultures examined. In marked contrast to its stimulatory effects on mu receptor messenger RNA levels and its lack of an effect on 6 receptor messenger RNA expression, interleukin-1beta reduced to 10-30% of control levels the kappa receptor messenger RNA levels in all cultures. Interleukin-1beta had no effect on the level of proenkephalin messenger RNA in cortical, striatal, cerebellar and hypothalamic cultures, but did significantly decrease the expression of proenkephalin messenger RNA in hippocampal cultures to 40% of the control level. Therefore, interleukin-1beta differentially regulated opioid receptor messenger RNA in astrocyte-enriched cultures in a manner dependent upon both the receptor type and the brain region from which the culture was derived. The cytokine also differentially regulated proenkephalin messenger RNA in a region-dependent fashion. These findings suggest a capacity for astrocytes to differentially regulate opioid peptide and receptor messenger RNAs in response to an immune factor, supporting the potential existence of a novel immune-opioid system interaction in the CNS.
Collapse
Affiliation(s)
- B B Ruzicka
- Mental Health Research Institute, University of Michigan, Ann Arbor 48109-0720, U.S.A
| | | |
Collapse
|
12
|
Abstract
Corticotropin-releasing factor (CRF) plays a major role at the level of the hypothalamus and pituitary to control the body's response mechanisms to stressful stimuli. The recent discovery of CRF outside the central nervous system suggests that CRF may well play a similar role in peripheral tissues, most likely in a paracrine manner. While its effects in many other peripheral tissues is not known yet, CRF and its receptors are upregulated in inflammatory pain states pointing to a key role under these circumstances. Indeed, locally expressed CRF seems to act on CRF receptors on immune cells which have migrated into the area of the inflamed tissue, and induce the release of opioid peptides synthesized within these immune cells. These opioids subsequently act on peripheral opioid receptors located on peripheral sensory nerves to inhibit the transmission of painful stimuli. CRF may also affect the inflammatory response; however, these data are still controversial. The peripheral paracrine effects of CRF may be similar to those of hypothalamic CRF, i.e., to counterbalance local stressful events, such as inflammation and pain, so that they do not threaten the homeostasis of the body. Interestingly, CRF-like peptides have been identified not only in mammalians, but also in species such as the frog (Stenzel-Poore et al., 1992, Mol. Endocrinol. 6, 1716) and the teleost fish (Okawara et al., 1988, Proc. Natl. Acad. Sci. USA 85, 8439) indicating that this is a peptide that has been conserved over a long period (200 million years) across species (Lederis et al., 1990, Prog. Clin. Biol. Res. 342, 467) and that the release of ACTH-like peptides by peptides of the CRF family may represent an ancestral type of stress response (Ottaviani et al., 1992, Gen. Comp. Endocrinol. 87, 354; Tran et al., 1990, Gen. Comp. Endocrinol. 78, 351).
Collapse
Affiliation(s)
- M Schäfer
- Behavioral Pharmacology and Genetics Section, National Institute on Drug Abuse, NIH, Baltimore, MD 21224, USA.
| | | | | |
Collapse
|
13
|
Chowdrey HS, Larsen PJ, Harbuz MS, Jessop DS, Aguilera G, Eckland DJ, Lightman SL. Evidence for arginine vasopressin as the primary activator of the HPA axis during adjuvant-induced arthritis. Br J Pharmacol 1995; 116:2417-24. [PMID: 8581278 PMCID: PMC1909046 DOI: 10.1111/j.1476-5381.1995.tb15089.x] [Citation(s) in RCA: 86] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
1. Adjuvant-induced arthritis (AA) is an experimental inflammation of the joints that results in chronic activation of the hypothalamo-pituitary-adrenal (HPA) axis. 2. In this study the role of hypothalamic corticotrophin-releasing factor (CRF) and arginine vasopressin (AVP) in the regulation of the HPA axis in this condition both in Sprague-Dawley (SD), and Piebald-Viral-Glaxo (PVG) rats has been further characterized. 3. The increase in AVP peptide content of portal blood (as early as day 11), just prior to the onset of arthritis is confirmed and further increases, peaking at day 16 are shown, coincident with the progression of inflammation in the PVG rats. 4. The increase in AVP is associated with a significant increase in the expression of AVP but not CRF mRNAs in the medial parvocellular division of the hypothalamic paraventricular nucleus (PVN) of arthritic SD rats. 5. In the presence of maximal inflammation of SD rats there was a significant decrease in the maximum binding of [125I]-Tyr-oCRF to anterior pituitary membranes, whereas AVP receptor concentration in anterior pituitary membranes from both PVG and SD rats showed a significant increase with respect to controls. 6. The basal adrenocorticotrophin (ACTH) secretion in vitro was similar in both control and arthritic SD rats but that from arthritic PVG rat pituitaries was significantly greater than the respective controls (436 +/- 91 v 167 +/- 23 pg/tube). The ACTH response of pituitaries of arthritic PVG rats to CRF or the combination of CRF and AVP was significantly higher compared with the controls, although the ACTH response of arthritic SD rat pituitaries was unchanged. 7. The results are consistent with the view that activation of the parvocellular vasopressin system has an important role in the adaptation of the HPA axis to experimentally-induced chronic stress of arthritis.
Collapse
Affiliation(s)
- H S Chowdrey
- Department of Medicine, Bristol Royal Infirmary, University of Bristol
| | | | | | | | | | | | | |
Collapse
|
14
|
Mélik Parsadaniantz S, Levin N, Lenoir V, Roberts JL, Kerdelhué B. Human interleukin 1 beta: corticotropin releasing factor and ACTH release and gene expression in the male rat: in vivo and in vitro studies. J Neurosci Res 1994; 37:675-82. [PMID: 7519272 DOI: 10.1002/jnr.490370602] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Numerous studies have shown that interleukin 1 (IL1), a cytokine secreted by macrophages, is capable of stimulating the hypothalamo-pituitary-adrenal (HPA) axis. Nevertheless, the sites involved in IL1 stimulation of the HPA axis remain, to date, subjects of controversy. In the present study, using in vivo and in vitro approaches, we tried to characterize the route by which IL1 acts on the HPA axis. In vivo, after an i.p. injection of human IL1 beta (1 microgram/rat), we measured plasma ACTH concentration, anterior pituitary (AP) ACTH content, hypothalamic (HT) corticotropin releasing factor (CRF) content, and also AP pro-opiomelanocortin (POMC) and HT CRF gene expression. ACTH and CRF were measured by specific radioimmunoassays (RIAs), and solution hybridization nuclease protection assay was used for quantification of nuclear POMC precursor RNA and nuclear and cytoplasmic POMC and CRF mRNA. Human IL1 beta provoked an increase in ACTH plasma concentration, a decrease in AP ACTH content, and a prolonged increase in AP POMC primary transcript levels (around 100%). A significant increase in AP POMC primary transcript content was evident 30 min after injection of hIL1 beta, while cytoplasmic POMC mRNA levels were increased in the AP only at 4 hr after injection of hIL1 beta. We did not observe an effect of hIL1 beta on either HT CRF content or HT CRF cytoplasmic mRNA levels. In order to characterize a possible direct effect of hIL1 beta at the AP level, we used an AP perifusion system to analyse the effect of hIL1 beta and CRH on ACTH release and on POMC gene expression.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
15
|
De Souza EB. Corticotropin-releasing factor and interleukin-1 receptors in the brain-endocrine-immune axis. Role in stress response and infection. Ann N Y Acad Sci 1993; 697:9-27. [PMID: 8257026 DOI: 10.1111/j.1749-6632.1993.tb49919.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
CRF and IL-1 receptors were identified, characterized, and localized in brain, endocrine, and immune tissues. CRF receptors with comparable kinetic and pharmacological characteristics were localized in the anterior and intermediate lobes of the pituitary, in brain areas involved in mediating stress responses, and in the macrophage-enriched marginal zones of the spleen. The discrete localization of IL-1 receptors in neurons of the hippocampus provides further support for the role of IL-1 as a neurotransmitter/neuromodulator/growth factor in the CNS. The neuroendocrine effects of IL-1 may be mediated through actions of the cytokine in brain. However, given the high densities of IL-1 receptors in the anterior pituitary and testis, direct effects of the cytokine at the pituitary or gonadal levels seem highly likely. Overall, these data support a role for IL-1 and CRF in coordinating and integrating the brain-endocrine-immune responses to physiological, pharmacological, and pathological stimuli.
Collapse
Affiliation(s)
- E B De Souza
- Neurocrine Biosciences, Inc., La Jolla, California 92037
| |
Collapse
|
16
|
Parnet P, Brunke DL, Goujon E, Mainard JD, Biragyn A, Arkins S, Dantzer R, Kelley KW. Molecular identification of two types of interleukin-1 receptors in the murine pituitary gland. J Neuroendocrinol 1993; 5:213-9. [PMID: 7683560 DOI: 10.1111/j.1365-2826.1993.tb00384.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The present study was carried out to characterize interleukin-1 (IL-1) receptors on murine pituitary cells. Receptor autoradiography confirmed the existence of binding sites for IL-1 alpha in the murine adenohypophysis, but not in the neural or intermediate lobes. Specific binding of IL-1 to isolated pituitary membranes revealed a Kd of 0.9 nM with a Bmax of 37 fmol/mg protein. To examine the possibility that the adenohypophysis synthesizes a receptor for IL-1, immunocytochemistry experiments with a specific monoclonal antibody against the type I receptor revealed the existence of this protein in only the adenohypophysis. Identity of the type I IL-1 receptor was similar to that found on T cells as determined by: 1) amplification of the predicted 619 bp fragment spanning the cytoplasmic, transmembrane and extracellular domains from RNA of pituitary and T cell origin, as well as clonal AtT-20 pituitary cells, and 2) restriction fragment analysis and sequencing of the amplified cDNAs. The pituitary gland and AtT-20 cells also expressed transcripts for the newly identified type II receptor for IL-1 as assessed by amplification of a specific 325 bp fragment, restriction fragment analysis and nucleotide sequencing, and these transcripts were similar to those found on B lymphocytes. These data identify two different forms of the IL-1 receptor in both normal and transformed pituitary cells and establish that these receptors are similar at the molecular level to those first identified on T and B lymphocytes.
Collapse
Affiliation(s)
- P Parnet
- INRA-INSERM, Unité de Recherches de Neurobiologie des Comportements, U 176, Bordeaux, France
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Parsadaniantz SM, Lenoir V, Terlain B, Kerdelhué B. Lack of effect of interleukins 1 alpha and 1 beta, during in vitro perifusion, on anterior pituitary release of adrenocorticotropic hormone and beta endorphin in the male rat. J Neurosci Res 1993; 34:315-23. [PMID: 8384268 DOI: 10.1002/jnr.490340308] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
It has been demonstrated that interleukin 1 (IL1) injection provokes a great variety of biological effects, notably an activation of the corticotropic axis, increasing plasma adrenocorticotropic hormone (ACTH) and corticosterone. However, the primary site of action of IL1 is still controversial. In the present study, we first verified the in vivo capability of human interleukins 1 alpha (hIL1 alpha) and 1 beta (hIL1 beta) to release ACTH and beta endorphin (beta EP) in the normal male rat, before investigating, through an anterior pituitary (AP) perifusion system, the hIL1 alpha and hIL1 beta effects on basal and corticotropin-releasing factor (CRF)-induced ACTH and beta EP secretions. This system enabled the examination of a dynamic profile of hormones secretion, avoiding the possibility of feedback mechanisms, as is the case with the use of regular but very often longtime incubations. The results showed that in a perifusion system, with a short duration treatment (below 2 hr) compatible with the kinetics of action observed in vivo, basal and CRF-induced ACTH and beta EP release were not modified in the presence of a broad range of concentrations (from 10(-12) to 10(-9) M) of hIL1 alpha or hIL1 beta. Taken together, these results clearly show that in an in vitro situation close to physiological conditions, the primary site of action of hIL1 alpha and hIL1 beta on ACTH and beta EP release is not located at the AP level in the male rat.
Collapse
Affiliation(s)
- S M Parsadaniantz
- Laboratoire de Neurobiologie de la Reproduction, CNRS-INRA, Jouy en Josas, France
| | | | | | | |
Collapse
|
18
|
Effects of Interleukin 1 on β-Endorphin Secretion in AtT-20 Pituitary Cells: Methods and Overview. ACTA ACUST UNITED AC 1993. [DOI: 10.1016/b978-0-12-185281-8.50024-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register]
|
19
|
Pfeilschifter J, Leighton J, Pignat W, Märki F, Vosbeck K. Cyclic AMP mimics, but does not mediate, interleukin-1- and tumour-necrosis-factor-stimulated phospholipase A2 secretion from rat renal mesangial cells. Biochem J 1991; 273(Pt 1):199-204. [PMID: 1846528 PMCID: PMC1149899 DOI: 10.1042/bj2730199] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
We have previously shown that recombinant interleukin 1 (IL-1) and recombinant tumour necrosis factor (TNF) synergistically stimulate phospholipase A2 release from mesangial cells. We now report that treatment of mesangial cells with the beta-agonist salbutamol, prostaglandin E2 (PGE2), cholera toxin or forskolin, which all activate adenylate cyclase, increased release of phospholipase A2 activity. Likewise, addition of a membrane-permeant cyclic AMP (cAMP) analogue or the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine enhanced release of phospholipase A2 activity from mesangial cells. There was a lag period of about 8 h before a significantly enhanced secretion could be detected. Furthermore, actinomycin D or cycloheximide completely suppressed cAMP-stimulated secretion of phospholipase A2. Angiotensin II, the phorbol ester phorbol 12-myristate 13-acetate, the Ca2+ ionophore A23187 and a membrane-permeant cGMP analogue did not stimulate phospholipase A2 release from the cells. Treatment with indomethacin completely inhibited IL-1 beta- and TNF-stimulated PGE2 synthesis, without having any effect on phospholipase A2 secretion, thus excluding cytokine-induced PGE2 synthesis as the mediator of phospholipase A2 release. Neither IL-1 beta nor TNF induced any increase in intracellular cAMP in mesangial cells. Furthermore, incubation of the cells with 2',5'-dideoxyadenosine, an inhibitor of adenylate cyclase, did not block cytokine-stimulated phospholipase A2 secretion. In addition, IL-1 beta and TNF synergistically interacted with forskolin to stimulate phospholipase A2 release from the cells. The protein kinase inhibitors H-8, staurosporine, K252a and amiloride inhibited IL-1 beta- and TNF-stimulated phospholipase A2 secretion. However, high concentrations that inhibit other protein kinases were needed. These observations suggest that IL-1 beta and TNF cause secretion of phospholipase A2 by a mechanism independent of cAMP. The signalling pathways used by IL-1 beta and TNF may involve a protein kinase that is probably different from protein kinase A or protein kinase C.
Collapse
Affiliation(s)
- J Pfeilschifter
- Research Department, Pharmaceuticals Division, Ciba-Geigy Ltd., Basel, Switzerland
| | | | | | | | | |
Collapse
|
20
|
Interleukin 1 induces beta-endorphin secretion via Fos and Jun in AtT-20 pituitary cells. Proc Natl Acad Sci U S A 1990; 87:7871-4. [PMID: 1978316 PMCID: PMC54852 DOI: 10.1073/pnas.87.20.7871] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Previous work had shown that interleukin 1 (IL-1), after a long period of treatment, stimulates beta-endorphin release and potentiates the effects of secretagogues in AtT-20 cells, a mouse anterior pituitary cell line. Treatment of AtT-20 cells with IL-1 induced a transient and early stimulation of mRNA expression by both immediate-early protooncogenes Fos and Jun (mouse c-fos and c-jun). The effect appeared within 30 min, and returned to basal levels after 2 hr. Desensitization of protein kinase C by phorbol ester pretreatment had no effect on the ability of IL-1 to induce Fos and Jun mRNA expression. Somatostatin, an inhibitor of cAMP and beta-endorphin secretion, did not reduce the IL-1 effect on Fos and Jun mRNA expression. Addition to AtT-20 cells of antisense oligonucleotides to Fos and Jun abolished the secretion induced by IL-1. These results indicate that immediate-early signals Fos and Jun are involved in IL-1-induced beta-endorphin secretion in AtT-20 cells.
Collapse
|
21
|
Dewhirst FE, Ago JM, Stashenko P. Interleukin 1 interacts synergistically with forskolin and isobutylmethylxanthine in stimulating bone resorption in organ culture. Calcif Tissue Int 1990; 47:1-7. [PMID: 1695117 DOI: 10.1007/bf02555859] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
This study examined the interaction of interleukin 1 (IL-1) with forskolin and isobutyl-methylxanthine (3-isobutyl-1-methyl-xanthine) (IBMX) in stimulating bone resorption in 5-day fetal rat long bone organ culture. Forskolin and IBMX are pharmacologic agents that elevate cyclic adenosine monophosphate (AMP) levels in many cell types, including osteoblasts and osteoclasts. The interaction of IL-1 with forskolin and IBMX are synergistic when submaximal resorptive concentrations of agonists were examined. Stimulated resorption was 2 to 5 times that expected for an additive response. When maximally resorptive concentrations of agonists were examined, the interaction between IL-1 and the other agents was, at most, additive. We have previously reported that parathyroid hormone and prostaglandin E, agents that also activate the cyclic AMP pathway in bone cells, interact synergistically with IL-1 in stimulating bone resorption. The results of this study, together with our previous studies, suggest that activation of the cyclic AMP pathway is a sufficient signal for an agent to interact synergistically with IL-1 in stimulating bone resorption.
Collapse
Affiliation(s)
- F E Dewhirst
- Department of Pharmacology, Forsyth Dental Center, Boston, Massachusetts 02115
| | | | | |
Collapse
|
22
|
Teschemacher H, Koch G, Scheffler H, Hildebrand A, Brantl V. Opioid peptides. Immunological significance? Ann N Y Acad Sci 1990; 594:66-77. [PMID: 2198841 DOI: 10.1111/j.1749-6632.1990.tb40468.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- H Teschemacher
- Rudolf Buchheim-Institut für Pharmakologie, Justus Liebig-Universität Giessen, Federal Republic of Germany
| | | | | | | | | |
Collapse
|
23
|
Abstract
A rapidly expanding body of evidence indicates that cytokines do indeed regulate pituitary hormone secretion. Recent studies with cytokines in vivo and in vitro support the idea that cytokines are the principal mediators of the neuroendocrine responses previously observed in infectious and inflammatory states. The dominant route of this modulation appears to be via the brain and hypothalamus, although a role for direct effects on the pituitary has not been excluded. These effects may be mediated by circulating cytokines, endogenously produced cytokines, or both. A number of receptor systems and second messengers may be involved, and a role for arachidonate metabolite pathways appears particularly likely. A final question: Of what use to the organism is the ability of immune activation to control pituitary hormone secretion? For some pituitary secretions there is a reasonable basis for speculation. Glucocorticoids serve to limit the severity of immune responses and recent studies argue that defects in this pathway permit the expression of autoimmune disease. Inhibition of thyroid function may limit the catabolic side effects of infectious illness. Stimulation of growth hormone could have the same effect, and growth hormone and prolactin may serve to enhance some immune responses.
Collapse
Affiliation(s)
- D E Scarborough
- Louisiana State University School of Medicine, Shreveport 71130
| |
Collapse
|
24
|
Făgărăşan MO, Bishop JF, Rinaudo MS, Axelrod J. Interleukin 1 induces early protein phosphorylation and requires only a short exposure for late induced secretion of beta-endorphin in a mouse pituitary cell line. Proc Natl Acad Sci U S A 1990; 87:2555-9. [PMID: 2157204 PMCID: PMC53728 DOI: 10.1073/pnas.87.7.2555] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Previous work has shown that prolonged pretreatment of a mouse anterior pituitary cell line, AtT-20 cells, with the cytokine interleukin 1 (IL-1) stimulates beta-endorphin release and potentiates the secretion induced by many secretagogues. Desensitization of protein kinase C (PKC) by pretreatment with phorbol ester [phorbol 12-tetradecanoate 13-acetate (TPA)] for 8 hr abolished the secretion induced by TPA as well as the enhancement of TPA-induced beta-endorphin release produced by IL-1. Desensitization of PKC only partly abolished the potentiating effects of IL-1 on corticotropin-releasing factor-induced beta-endorphin secretion. In contrast, IL-1-induced beta-endorphin release was independent of PKC. We observed that treatment of AtT-20 cells with IL-1 markedly phosphorylated 19-, 20-, and 60-kDa proteins within minutes, presumably by early activation of protein kinases. Prolonged treatment with TPA, which was shown to desensitize an 87-kDa protein (a substrate for PKC), had no effect on IL-1-induced phosphorylation of 20-, 60-, and 87-kDa proteins, indicating that the phosphorylation of these proteins does not involve PKC. IL-1 does not generate cAMP in AtT-20 cells, suggesting that a cAMP-dependent protein kinase is also not involved. Prolonged treatment with IL-1 abolishes the capacity of cytokine to induce the phosphorylation of 20- and 60-kDa proteins. The presence of IL-1 was required initially only for a short time to induce late secretion in AtT-20 cells. These observations indicate that once IL-1 generates an early signal, its presence is no longer necessary for the subsequent secretion of beta-endorphin.
Collapse
Affiliation(s)
- M O Făgărăşan
- Laboratory of Cellular Biology, National Institute of Mental Health, Bethesda, MD 20892
| | | | | | | |
Collapse
|
25
|
Făgărăşan MO, Axelrod J. Interleukin-1 amplifies the action of pituitary secretagogues via protein kinases. Int J Neurosci 1990; 51:311-3. [PMID: 2279892 DOI: 10.3109/00207459008999729] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- M O Făgărăşan
- Clinical Neuroscience Branch, National Institute of Mental Health and Peptide Design, Bethesda, Maryland 20892
| | | |
Collapse
|
26
|
Affiliation(s)
- E J Goetzl
- Howard Hughes Medical Institute, University of California Medical Center, San Francisco 94143
| | | | | |
Collapse
|
27
|
Eskay RL, Grino M, Chen HT. Interleukins, signal transduction, and the immune system-mediated stress response. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1990; 274:331-43. [PMID: 2239431 DOI: 10.1007/978-1-4684-5799-5_21] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Overwhelming evidence indicates that the administration of cytokines such as IL-1 alpha and beta, IL-6, and TNF-1 alpha stimulates one or more components of the HPA axis. The hypothesis driving this research is that host infection and tissue injury trigger the synthesis and release of several cytokines that act locally at sites of trauma and distally upon entering the circulation. Available evidence suggests that the primary source of HPA axis-acting or circulating cytokines is activated monocytes or macrophages; therefore, a direct relationship should exist between the appearance of monokines in plasma and the subsequent appearance of pituitary-adrenocortical hormones in plasma as well. Clarification of the physiological role of monokines as mediators of the host stress response will come from in vivo studies in which the type, sequence of appearance, duration of elevation, and quantification of each monokine is monitored along with ACTH and glucocorticoids, following an appropriate immune challenge. In several recent reports, investigators have administered bacterial-derived endotoxin or LPS to stimulate the physiological events associated with infection or injury and chronicled plasma levels of IL-1, IL-6, and TNF-alpha (37,56,57). In human subjects, endotoxin challenge enhanced plasma TNF-alpha levels by 1 hour, which returned to basal levels by 4 hours (37), whereas, IL-6 plasma activity increased at 2 hours post-challenge and returned to baseline by 6 hours (56). Thus, both of these monokines are implicated as possible acute activators of the HPA axis. In perhaps the most revealing study to date, LPS challenge of mice indicated both a differential appearance and disappearance rate in serum for TNF-alpha and IL-1 and a differential regulation of these monokines by glucocorticoid feedback (57). Serum TNF was detected 45 minutes post-LPS, peaked by 1 hour, and returned to control levels by 3 hours. Serum corticosterone concentrations rose rapidly over a time course similar to that of TNF. Even after serum TNF concentration had returned to basal conditions, corticosterone levels remained maximally elevated, and serum corticosterone was still significantly above basal levels 24-hour post-LPS. The rapid return of circulating TNF to pre-LPS challenge levels appeared to be regulated by negative glucocorticoid feedback, because TNF remained maximally elevated for at least 6 hours in adrenalectomized or hypophysectomized mice. LPS-induced levels of IL-1 were delayed as compared to serum TNF, peaked at 4 hours, and remained elevated even at 24 hours.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- R L Eskay
- Laboratory of Clinical Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD 20892
| | | | | |
Collapse
|